Brooke Story - 14 Jun 2021 Form 4 Insider Report for Sigilon Therapeutics, Inc.

Role
Director
Signature
/s/ Matthew Kowalsky, Attorney-in-Fact
Issuer symbol
N/A
Transactions as of
14 Jun 2021
Net transactions value
$0
Form type
4
Filing time
16 Jun 2021, 16:10:19 UTC
Next filing
27 May 2022
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction SGTX Stock Option (Right to Buy) Award $0 +17,777 $0.000000 17,777 14 Jun 2021 Common Stock 17,777 $11.19 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The option vest as to one-third of the shares on each of June 14, 2022, June 14, 2023 and June 14, 2024.